Joe McCann, Point Biopharma CEO
June 3, 2021 01:40 PM EDTUpdated 01:56 PM
R&D
Manufacturing

Just months af­ter SPAC re­verse merg­er, Point Bio­phar­ma ups the ante at In­di­anapo­lis man­u­fac­tur­ing site

Josh Sullivan

Point Bio­phar­ma trot­ted out to near-uni­corn sta­tus in March as part of a re­verse merg­er with a SPAC backed by RA Cap­i­tal’s Pe­ter Kolchin­sky …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

FDA meet­ing to pick next win­ter's flu shot is can­celed, in omi­nous sign for US vac­cine pol­i­cy

Up­dat­ed: Lil­ly joins Trump ad­min­is­tra­tion to an­nounce $27B man­u­fac­tur­ing com­mit­ment

Af­ter re­jec­tion, Re­gen­eron seeks ac­cel­er­at­ed ap­proval of bis­pe­cif­ic for on­ly one of two types of lym­phoma

As­traZeneca’s SERD hits pri­ma­ry end­point in late-stage tri­al, but first-line po­ten­tial re­mains un­cer­tain

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times